Updated 2026-09 · 4 min read
Half-life is how long it takes a compound's concentration to fall by half in a given system. In preclinical work it drives protocol timing — sampling windows, wash-out intervals, and how a result is interpreted over time. The figures below are approximate, drawn from published literature, and vary with model, formulation, and assay.
| Compound | Class | Reported half-life |
|---|---|---|
| Burn-R (triple agonist) | GIP/GLP-1/glucagon | ~6 days |
| Burn-T (dual agonist) | GIP/GLP-1 | ~5 days |
| Burn-S (GLP-1 agonist) | GLP-1 | ~7 days |
| BPC-157 | Pentadecapeptide | Short (minutes, in vitro) |
| TB-500 (Tβ4 fragment) | Actin-binding | Intermediate |
| GHK-Cu | Copper tripeptide | Short |
| Semax | ACTH(4-10) analog | Short (extended vs native) |
The long circulating half-lives of the metabolic agonists are a function of structural modifications — fatty-acid acylation and sequence changes — that resist enzymatic clearance. The shorter-lived peptides are studied on correspondingly shorter timescales, and are more sensitive to reconstitution and storage handling.
This material is synthesized from publicly available preclinical literature and industry documentation for qualified laboratory researchers. It is not medical, veterinary, therapeutic, or diagnostic advice. All compounds are supplied and discussed solely for in-vitro laboratory research and are not for human or animal use.